Journal article
Antibodies in lymphocyte supernatants can distinguish between neutralising antibodies induced by RSV vaccination and pre-existing antibodies induced by natural infection
- Abstract:
-
Introduction Respiratory syncytial virus (RSV) is the single most important cause of severe respiratory illness in infants. There is no effective vaccine and the only effective treatment available is the monoclonal antibody palivizumab which reduces the risk of severe RSV disease in prematurely born infants. However, palivizumab is too costly to allow for wide implementation and thus treatment is restricted to supportive care. Despite extensive efforts to develop a vaccine, p... Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 1.1MB, Terms of use)
-
(Preview, Accepted manuscript, pdf, 190.9KB, Terms of use)
-
(Preview, Accepted manuscript, pdf, 252.0KB, Terms of use)
-
- Publisher copy:
- 10.1016/j.vaccine.2018.09.070
Authors
Funding
Bibliographic Details
- Publisher:
- Elsevier
- Journal:
- Vaccine More from this journal
- Volume:
- 36
- Issue:
- 46
- Pages:
- 6988-6994
- Publication date:
- 2018-10-11
- Acceptance date:
- 2018-09-29
- DOI:
- EISSN:
-
1873-2518
- ISSN:
-
0264-410X
- Pmid:
-
30318168
Item Description
- Language:
-
English
- Keywords:
- Pubs id:
-
pubs:928824
- UUID:
-
uuid:3fbfa840-27b4-4cbe-915a-bb55fc1ef02f
- Local pid:
-
pubs:928824
- Source identifiers:
-
928824
- Deposit date:
-
2018-10-20
Terms of use
- Copyright holder:
- Elsevier Ltd
- Copyright date:
- 2018
- Notes:
- Copyright © 2018 Elsevier Ltd. This is the accepted manuscript version of the article. The final version is available online from Elsevier at: https://doi.org/10.1016/j.vaccine.2018.09.070
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record